To further confirm the role of CXCL2 in NFATc3-mediated pulmonary fibrosis, we administered recombinant mouse CXCL2 (rmCXCL2), intratracheally into NFATc3+/- mice, 8 days after BLM (i.t) stimulation (Fig. 9C). The gene discussed is CXCL2; the disease is pulmonary fibrosis.